Published in Ann N Y Acad Sci on October 31, 1996
Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond) (2005) 3.00
Chronic helminth infection induces alternatively activated macrophages expressing high levels of CCR5 with low interleukin-12 production and Th2-biasing ability. Infect Immun (2002) 1.41
Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest (1998) 1.20
Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect Immun (2001) 0.98
A type 2 response in lipopolysaccharide (LPS)-stimulated whole blood cell cultures from periodontitis patients. Clin Exp Immunol (2002) 0.85
Transcriptional inhibition of interleukin-12 promoter activity in Leishmania spp.-infected macrophages. J Parasitol (2008) 0.85
Monocyte-derived RANTES is intrinsically elevated in periodontal disease while MCP-1 levels are related to inflammation and are inversely correlated with IL-12 levels. Clin Exp Immunol (2003) 0.82
Enhanced prostaglandin E2 production by monocytes in atopic dermatitis (AD) is not accompanied by enhanced production of IL-6, IL-10 or IL-12. Clin Exp Immunol (1998) 0.81
Integration of cytogenetic landmarks into the draft sequence of the human genome. Nature (2001) 10.96
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci (1975) 5.23
Increased plasma levels of interleukin-6 in sepsis. Blood (1989) 3.92
Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol (1988) 3.51
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J Exp Med (1995) 2.98
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med (1995) 2.89
Molecular and quantitative analysis of helper T cell-replacing factors on the induction of antigen-sensitive B and T lymphocytes. J Immunol (1979) 2.79
IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J Immunol (1997) 2.67
Interleukin 6 is involved in interleukin 1-induced activities. Eur J Immunol (1988) 2.63
Molecular cloning and expression of hybridoma growth factor in Escherichia coli. J Immunol (1987) 2.59
Serum levels of interleukin-6 and acute phase responses. Lancet (1987) 2.44
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity (2002) 2.31
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol (1988) 2.24
Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum (1979) 2.23
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med (1994) 2.13
Regulatory properties of LFA-1 alpha and beta chains in human T-lymphocyte activation. Nature (1988) 2.09
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest (1992) 2.04
Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD 23 is a low affinity receptor for IgE. J Immunol (1987) 1.99
In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum (1994) 1.96
The purification and quantitation of helper T cell-replacing factors secreted by murine spleen cells activated by concanavalin A. J Immunol (1979) 1.95
Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. J Biol Chem (1991) 1.92
Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun (1992) 1.85
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum (2000) 1.84
Anti-DNA antibodies and lupus nephritis: the complexity of crossreactivity. Immunol Today (1990) 1.84
A growth-factor dependent B-cell hybridoma. Curr Top Microbiol Immunol (1986) 1.79
The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun (1988) 1.76
An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun (1999) 1.75
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol (1996) 1.74
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood (1991) 1.73
An agarose mercurial column for the separation of mercaptopapain and nonmercaptopapain. Biochim Biophys Acta (1970) 1.70
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer (1997) 1.70
Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol (1995) 1.69
Immunology of DNA. IV. Quantitative aspects of the Farr assay. J Immunol Methods (1976) 1.66
Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun (1989) 1.64
Immunology of DNA. I. The influence of reaction conditions on the Farr assay as used for the detection of anti-ds DNA. J Immunol Methods (1976) 1.63
Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol (1993) 1.62
Role of cytokines in sepsis. Adv Immunol (1997) 1.60
Transcription of kinetoplast DNA in Trypanosoma brucei bloodstream and culture forms. Plasmid (1981) 1.58
Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest (1994) 1.54
Circulating interleukin-6 receptor in patients with sepsis syndrome. J Infect Dis (1995) 1.50
Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum (1992) 1.43
Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw (1991) 1.42
Characterization of the autoantigen calreticulin. J Immunol (1991) 1.42
[Immunology in medical practice. XXI. Laboratory tests for immunologic diseases]. Ned Tijdschr Geneeskd (1999) 1.39
Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-T CD4+ monoclonal antibody (B-F5) Clin Exp Rheumatol (1992) 1.39
Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood (1995) 1.39
Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta (1991) 1.38
Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood (1994) 1.37
Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw (1994) 1.35
Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis (1982) 1.35
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia (2000) 1.35
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis (2006) 1.34
Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies. Eur J Immunol (1988) 1.34
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol (1998) 1.33
Detection of antibodies to DNA by radioimmunoassay and immunofluorescence. Scand J Rheumatol Suppl (1975) 1.30
Treatment of corticosteroid resistant acute graft-versus-host disease by in vivo administration of anti-interleukin-2 receptor monoclonal antibody (B-B10) Blood (1990) 1.30
Epitope mapping of recombinant human gamma interferon using monoclonal antibodies. Mol Immunol (1989) 1.27
Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems. Eur J Immunol (1987) 1.27
A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood (1998) 1.27
Cross-reactive binding patterns of monoclonal antibodies to DNA are often caused by DNA/anti-DNA immune complexes. Res Immunol (1989) 1.26
Development of a human interleukin-6 receptor antagonist. J Biol Chem (1994) 1.25
Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. J Immunol (1990) 1.25
Evidence for a polypeptide segment at the carboxyl terminus of recombinant human gamma interferon involved in expression of biological activity. Biochemistry (1988) 1.24
Anti-DNA antibodies can bind to the glomerulus via two distinct mechanisms. Kidney Int (1992) 1.24
Induction of immunoglobulin synthesis by interleukin 2 is T4+/T8- cell dependent. A role for interleukin 2 in the pokeweed mitogen-driven system. Eur J Immunol (1985) 1.24
IL-6 is an intermediate in IL-1-induced thymocyte proliferation. J Immunol (1989) 1.23
Functional association between the human myeloid immunoglobulin A Fc receptor (CD89) and FcR gamma chain. Molecular basis for CD89/FcR gamma chain association. J Biol Chem (1995) 1.23
Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases. Scand J Rheumatol (1988) 1.22
Histone and DNA detection in swollen spermatozoa and somatic cells, by immunofluorescence. Clin Exp Immunol (1976) 1.21
Detection of anti-dsDNA as diagnostic tool. Ann Rheum Dis (1981) 1.21
Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford) (2003) 1.20
Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. J Immunol (1997) 1.20
The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur Cytokine Netw (1997) 1.20
Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood (1995) 1.20
Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest (1998) 1.20
Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood (1991) 1.19
Activation of toll-like receptors 2 and 4 by gram-negative periodontal bacteria. Oral Microbiol Immunol (2007) 1.18
Effects on leukocytes after injection of tumor necrosis factor into healthy humans. Blood (1992) 1.17
High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol (1992) 1.17
Immobilized anti-CD3 monoclonal antibodies induce accessory cell-independent lymphokine production, proliferation and helper activity in human T lymphocytes. Immunology (1989) 1.15
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother (1992) 1.15
Interleukin-6 and its relation to the humoral immune response and clinical parameters in burned patients. Surgery (1991) 1.14
Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol (2001) 1.14
Cross-reactivity of monoclonal anti-DNA antibodies with heparan sulfate is mediated via bound DNA/histone complexes. J Autoimmun (1990) 1.14
Interleukin-6 mediates host defense responses induced by abdominal surgery. Surgery (1993) 1.13
Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol (1998) 1.13
Interleukin-13 is produced by activated human CD45RA+ and CD45RO+ T cells: modulation by interleukin-4 and interleukin-12. Eur J Immunol (1996) 1.13